Freedom of Information Act Request – Reference Foi/13/116 New Drugs Added to Formulary

Total Page:16

File Type:pdf, Size:1020Kb

Freedom of Information Act Request – Reference Foi/13/116 New Drugs Added to Formulary Freedom of Information Act Request – Reference FoI/13/116 New Drugs Added to Formulary Request details Please will you provide me with numbers of new drugs that your LHB has introduced over the past three years, listing the number of new drugs introduced by year in each of those years? Response 2010 = 41 2011 = 53 2012 = 71 2010 Generic Name 1. adalimumab, etanercept, infliximab, rituximab and abatacept 2. beclometasone and formoterol (Fostair®) 3. bortezomib (Velcade®) in combination with melphalan and prednisone 4. Brinzolamide/timolol (Azarga®) 5. bromocriptine 6. calcium and vitamin D3 (Calceos®) 7. calcium and vitamin D (Adcal D3 Dissolve®) 8. capecitabine 9. Carmellose eye drops (Optive®) 10. Certolizumab pegol 11. Darunavir (Prezista®▼) 12. epoetin alfa (Binocrit®) 13. epoetin theta (Eporatio®) 14. Eslicarbazepine acetate (Zebinix®) 15. Evicel 16. fentanyl buccal tablets (Effentora) 17. fentanyl intranasal spray (Instanyl®) 18. Fesoterodine (Toviaz®) 19. filgrastim (TevaGrastim®) 20. filgrastim (Zarzio®) 21. gefitinib 22. infliximab and adalimumab 23. liraglutide (Victoza®) 24. Loperamide tablets 25. losartan 26. Mepilex® Ag 27. Movicol Paediatric 28. Nebuchamber 29. paclitaxel albumin (Abraxane®) monotherapy 30. pemetrexed 31. Plerixafor (Mozobil®q) 32. pramipexole prolonged release (Mirapexin®) 33. Prontosan® wound irrigation solution and gel 34. quinagolide (Norprolac®) 35. raltegravir (Isentress®) 36. rituximab sildenafil (Revatio®) tablets 2010 Generic Name 37. sodium chloride (7%) Nebusal® 38. somatropin (NutropinAq®) 39. Topotecan 40. Trabectedin 41. Xamiol 2011 Generic Name 1. artemether and lumefantrine (Riamet®) 2. artesunate 3. atazanavir (Reyataz®) co-administered with low dose ritonavir 4. azacitidine 5. aztreonam (Azactam®) 6. bendamustine 7. Bivalirudin 8. Bortezomib 9. Calcium acetate and magnesium carbonate (Osvaren®) 10. darunavir (Prezista®) 11. denosumab (Prolia®) 12. Dermacolor 13. Calcium carbonate and cholecalciferol caplets (Calcichew-D3 500mg/400unit caplets®) 14. capecitabine 15. capsaicin 0.025% cream (Zacin®) 16. Combodart® (Dutasteride and tamsulosin) 17. Dexamethasone intravitreal implant (Ozurdex) 18. Dronedarone 19. Fentanyl (PecFent®) 20. Ferric carboxymaltose (Ferinject®) 21. filgrastim (Nivestim®) 22. fluticasone furoate (Avamys®) nasal spray (Avamys®) 23. Frovatriptan (Migard®) 24. golimumab 25. golimumab 26. golimumab Grass pollen extract (Grazax) 27. Hydromol ointment (yellow soft paraffin 30%, liquid paraffin 40% emulsifying wax 30%) 28. Indapamide 2.5mg 29. Keromask 30. lidocaine 4% topical sterile solution. Laryngojet brand 31. Malarone Adult and paediatric 32. memantine, donepezil, galantamine, rivastigmine 33. Mifarmutide 34. naftidrofuryl Nortriptyline in Neuropathic Pain 35. pazopanib 36. prucalopride 37. ranolazine (Ranexa®) 38. retigabine 39. rituximab 2011 Generic Name 40. romiplostim 41. saxagliptin (Onglyza®) 42. sildenafil (Revatio®) solution for injection 43. Sitagliptin 50mg and metformin 1g (Janumet®) 44. sodium hyaluronate eye drops 0.1%, 0.2% (HYLO-Tear, HYLO-Forte) 45. Sunitinib (Sutent®) 46. Valganciclovir (Valcyte®) tablets 47. Valganciclovir (Valcyte®) powder for oral solution 48. Thalidomide 49. tipranavir (Aptivus®) capsules (co-administered with low dose ritonavir) 50. tipranavir (Aptivus®) oral solution, (co-administered with low dose ritonavir) 51. Tisseel Ready to Use (RTU) 52. trospium chloride prolonged release (Regurin XL®) 53. Tenofovir disoproxil fumarate (Viread®) 2012 Generic Name 1. Abiraterone Alteplase (Actilyse® Cathflo® 2 mg) 2. Adalimumab (Humira®▼) 3. apixaban 4. Argatroban 5. Baclofen intrathecal 6. Balneum Plus cream 7. Boceprevir 8. Botulinum toxin type A 9. Botulinum toxin A – Xeomin brand Bupivacaine hydrochloride/ fentanyl solution for infusion (Bufyl®) 10. Calcipotriol & betamethasone (Dovobet® gel) 11. Capsaicin 8% patch (Qutenza®▼) 12. clopidogrel 13. Collagenase Clostridium histolyticum (Xiapex®) 14. colecalciferol (Dekristol®) 15. colecalciferol 800iu capsules (Fultium®) 16. Consilient brand Oral Contraceptives 17. Dabigatran etexilate 18. darunavir (Prezista®) 400 mg once daily, co-administered with low dose ritonavir, 19. Denosumab Dexmedetomidine (Dexdor®) 2012 Generic Name 20. Dihydroartemisinin / piperaquine phosphate (Eurartesim®) 21. Dimeticone (Hedrin®) 22. docusate sodium oral liquid 23. Duloxetine 24. Emollient cream with urea plus steroid (Hydromol HC intensive – Urea 10% plus hydrocortisone 1%) 25. Emtricitabine / rilpivirine / tenofovir (Eviplera®) 26. eltrombopag for ITP 27. Entecavir (Baraclude®▼) 28. Eslicarbazepine acetate (Zebinix®) 29. Esomeprazole (Nexium® IV) 30. etanercept, infliximab, adalimumab 31. Everolimus (Afinitor®) 32. Exenatide prolonged-release suspension for injection (Bydureon) 33. Fingolimod 34. Fluorouracil/salicylic acid (Actikerall®) fluticasone propionate/formoterol fumarate (Flutiform MDI®) 35. Formoterol Easyhaler 36. hyaluronic acid (HYDEAL-D) (Hyalofemme®) 37. Icatibant (Firazyr®▼) 38. Levobupivacaine infusion (Chirocaine®) 39. Lymecycline 40. Mercaptamine (Cystagon®) 41. Mercaptopurine (Xaluprine®) 20mg/ml oral suspension 42. Midazolam (Buccolam®▼) 43. Morphine sulphate SR (Morphgesic) Naltrexone 44. Nevirapine 400 mg prolonged release tablets (Viramune) 45. Nicotinic acid with laropripant (Tredaptive®) 46. Nilotinib 47. nilotinib 48. Paliperidone palmitate (Xeplion®) prolonged release suspension for injection 49. Pantoprazole 50. pharmalgen 51. Raltitrexed 52. Ramipril oral solution 53. rifaximin (Xifaxanta®) 54. rilpivirine (Edurant®) 55. rituximab 56. Rosuvastatin 57. Rufinamide (Inovelon®) 40 mg/ml oral suspension saxagliptin (Onglyza®) 58. Sevelamer carbonate (Renvela) NB tablet form 59. Sodium hyaluronate bladder instillation (Cystistat) 60. sodium hyaluronate + chondroitin sulphate bladder instillation (iAluril) 61. Sodium valproate (Episenta®) 2012 Generic Name 62. sugammadex (Bridion®) 63. Tapentadol (Palexia SR®) 64. Telaprevir 65. Testosterone gel (Testim®) 66. Testosterone gel (Testogel®) 67. Testosterone undecanoate (Nebido®) 68. Trastuzumab (Herceptin®) 150 mg powder for concentrate for solution for infusion 69. Urea 10% cream (Hydromol Intensive) 70. Vancogenx 71. Vitamin A Eye Ointment (VitA-POS®) .
Recommended publications
  • (Epoetin and Darbepoetin) for Treating Cancer Treatment-Induced Anaemia (Including Review of Technology Appraisal No
    HEALTH TECHNOLOGY ASSESSMENT VOLUME 20 ISSUE 13 FEBRUARY 2016 ISSN 1366-5278 The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model Louise Crathorne, Nicola Huxley, Marcela Haasova, Tristan Snowsill, Tracey Jones-Hughes, Martin Hoyle, Simon Briscoe, Helen Coelho, Linda Long, Antonieta Medina-Lara, Ruben Mujica-Mota, Mark Napier and Chris Hyde DOI 10.3310/hta20130 The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model Louise Crathorne,1* Nicola Huxley,1 Marcela Haasova,1 Tristan Snowsill,1 Tracey Jones-Hughes,1 Martin Hoyle,1 Simon Briscoe,1 Helen Coelho,1 Linda Long,1 Antonieta Medina-Lara,2 Ruben Mujica-Mota,1 Mark Napier3 and Chris Hyde1 1Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK 2University of Exeter Medical School, Exeter, UK 3Royal Devon and Exeter Hospital, Exeter, UK *Corresponding author Declared competing interests of authors: none Published February 2016 DOI: 10.3310/hta20130 This report should be referenced as follows: Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, et al. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model. Health Technol Assess 2016;20(13). Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/ Clinical Medicine.
    [Show full text]
  • Biosimilar Epoetins and Other ``Follow-On
    Biosimilar epoetins and other “follow-on” biologics: Update on the European experiences Wolfgang Jelkmann To cite this version: Wolfgang Jelkmann. Biosimilar epoetins and other “follow-on” biologics: Update on the European experiences. American Journal of Hematology, Wiley, 2010, 85 (10), pp.771. 10.1002/ajh.21805. hal-00552331 HAL Id: hal-00552331 https://hal.archives-ouvertes.fr/hal-00552331 Submitted on 6 Jan 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. American Journal of Hematology Biosimilar epoetins and other “follow-on” biologics: Update on the European experiences For Peer Review Journal: American Journal of Hematology Manuscript ID: AJH-10-0229.R1 Wiley - Manuscript type: Critical Review Date Submitted by the 10-Jun-2010 Author: Complete List of Authors: Jelkmann, Wolfgang; University, Physiology Anemias, Erythropoietin, Hematology- medical, Neutropenia, Keywords: Pharmacology John Wiley & Sons Page 1 of 30 American Journal of Hematology 1 2 3 Table II. Benefits and problems related to the use of biosimilars 4 5 ________________________________________________________________ 6 Benefits Problems 7 ______________________________________________________________________ 8 9 10 Lower pricing than originator medicines Lack of long-term experience 11 (efficacy, safety, immunogenicity?) 12 13 Pressure on innovator companies Product-specific administration routes 14 15 to reduce prices of originator medicines (s.c.
    [Show full text]
  • The Curtailment of the European Medicines Agency’S Policy on Access to Documents
    Supplementary Online Content Doshi P. Transparency interrupted: the curtailment of the European Medicines Agency’s policy on access to documents. JAMA Intern Med. Published online August 19, 2013. doi:10.1001/jamainternmed.2013.9989 eAppendix. Table of European Medicines Agency Freedom of Information Requests Snapshot Dated June 4, 2013 This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Category of documents Category of documents Affiliation according to Closed Product / subject Pages requested requested social and occupational Received Pending Replied released DOSSIER NON-DOSSIER profile Open Mixed documents Academia/Research Avandia (rosiglitazone) institute 14/12/10 Closed 13/01/11 1,048 Somatropin Studies Other 13/12/10 Closed 14/01/11 0 Tasocitinib Dossier, SA Legal 16/12/10 Closed 18/01/11 0 Duloxetines: Module 5 Ariclaim; Cymbalta; Xeristar; Yentreve Healthcare professional 15/12/10 Closed 16/05/11 13,731 Infanrix HepB Mixed documents Legal 16/12/10 Closed 16/02/11 247 AR, minutes, Dossier, CSR Avonex (interferon beta-1a) Healthcare professional 30/11/10 Closed 04/02/11 18 Travatan (travoprost) AR, PSUR Media 21/12/10 Closed 21/01/11 474 PhVWP H1N1 (pandemic influenza vaccine) EU Institution (EC etc) 20/10/10 Closed 08/02/11 42 Plavix (clopidogrel) CSR Media 04/01/11 Closed 06/09/12 70,291 Referral documents Agreal (veralipride) Patients organisation
    [Show full text]
  • Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (Esas) Still Covered by P
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Erasmus University Digital Repository RESEARCH ARTICLE Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis- Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study Ylenia Ingrasciotta1☯, Francesco Giorgianni1☯, Ilaria Marcianò1☯, Jenny Bolcato2☯, a11111 Roberta Pirolo2☯, Alessandro Chinellato2☯, Valentina Ientile1☯, Domenico Santoro3☯, Armando A. Genazzani4☯, Angela Alibrandi5☯, Andrea Fontana6☯, Achille P. Caputi1,7☯, Gianluca Trifirò1,7,8☯* 1 Unit of Clinical Pharmacology, A.O.U. Policlinico ‘‘G. Martino”, Messina, Italy, 2 Treviso Local Health Unit, Treviso, Italy, 3 Department of Clinical and Experimental Medicine, AOU Policlinico “G. Martino”, University of Messina, Messina, Italy, 4 Department of Pharmaceutical Sciences, ''A. Avogadro'' University, Novara, Italy, 5 Department of Economic Sciences, University of Messina, Messina, Italy, 6 Unit of Biostatistics, OPEN ACCESS IRCCS ‘‘Casa Sollievo della Sofferenza”, San Giovanni Rotondo, FG, Italy, 7 Department of Biomedical and Dental Sciences and Morpho-functional Imaging, University of Messina, Messina, Italy, 8 Department of Citation: Ingrasciotta Y, Giorgianni F, Marcianò I, Medical Informatics, Erasmus Medical Center, Rotterdam, Netherlands Bolcato J, Pirolo R, Chinellato A, et al. (2016) Comparative Effectiveness of Biosimilar, Reference ☯ These authors contributed equally to this work. Product and Other Erythropoiesis-Stimulating Agents * [email protected] (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population- Based Study. PLoS ONE 11(5): e0155805. doi:10.1371/journal.pone.0155805 Abstract Editor: Lorenzo Giovanni Mantovani, FEDERICO II UNIVERSITY OF NAPLES, ITALY Background Received: January 13, 2016 Since 2007 biosimilars of erythropoiesis-stimulating agents (ESAs) are available on the Ital- Accepted: May 4, 2016 ian market.
    [Show full text]
  • Peginesatide for Anaemia in Chronic Kidney Disease – First and Second Line
    Peginesatide for anaemia in chronic kidney disease – first and second line June 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes. The NIHR Horizon Scanning Centre Research Programme is part of the National Institute for Health Research www.nhsc-healthhorizons.org.uk June 2012 Peginesatide for anaemia in chronic kidney disease – first and second line Target group • Symptomatic anaemia: patients on dialysis with chronic kidney disease (CKD) – first and second line. Background Human erythropoietin (EPO) is a protein produced by the kidneys that stimulates the production of red blood cells. Because the kidney is the sole source of EPO synthesis in adults, the reduction in kidney mass that occurs in progressive CKD often causes impairment of EPO production, resulting in anaemia. Technology description Peginesatide (AF-37702) is a synthetic peptide mimetic of EPO that binds directly to the erythropoietin receptor on red blood cell precursors to stimulate red cell formation. Peginesatide is intended as a substitute for currently available erythropoiesis stimulating agents (ESAs) in the treatment of anaemia in CKD dialysis patients. It is administered intravenously (IV) or subcutaneously (SC) at 0.04 mg/kg once monthly. After the initial dose, doses may be titrated to achieve a haemoglobin (Hb) level in the range of 10 to 12g/dL. Peginesatide is also in phase II clinical trials for pure red cell aplasia.
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]
  • Somamer Reagents Generated to Human Proteins Number Somamer Seqid Analyte Name Uniprot ID 1 5227-60
    SOMAmer Reagents Generated to Human Proteins The exact content of any pre-specified menu offered by SomaLogic may be altered on an ongoing basis, including the addition of SOMAmer reagents as they are created, and the removal of others if deemed necessary, as we continue to improve the performance of the SOMAscan assay. However, the client will know the exact content at the time of study contracting. SomaLogic reserves the right to alter the menu at any time in its sole discretion. Number SOMAmer SeqID Analyte Name UniProt ID 1 5227-60 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Q15118 2 14156-33 14-3-3 protein beta/alpha P31946 3 14157-21 14-3-3 protein epsilon P62258 P31946, P62258, P61981, Q04917, 4 4179-57 14-3-3 protein family P27348, P63104, P31947 5 4829-43 14-3-3 protein sigma P31947 6 7625-27 14-3-3 protein theta P27348 7 5858-6 14-3-3 protein zeta/delta P63104 8 4995-16 15-hydroxyprostaglandin dehydrogenase [NAD(+)] P15428 9 4563-61 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 P19174 10 10361-25 2'-5'-oligoadenylate synthase 1 P00973 11 3898-5 26S proteasome non-ATPase regulatory subunit 7 P51665 12 5230-99 3-hydroxy-3-methylglutaryl-coenzyme A reductase P04035 13 4217-49 3-hydroxyacyl-CoA dehydrogenase type-2 Q99714 14 5861-78 3-hydroxyanthranilate 3,4-dioxygenase P46952 15 4693-72 3-hydroxyisobutyrate dehydrogenase, mitochondrial P31937 16 4460-8 3-phosphoinositide-dependent protein kinase 1 O15530 17 5026-66 40S ribosomal protein S3 P23396 18 5484-63 40S ribosomal protein
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • WO 2017/120178 Al 13 July 2 0 17 (13.07.2017) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/120178 Al 13 July 2 0 17 (13.07.2017) W P O P C T (51) International Patent Classification: (72) Inventors: BADELT, Steven, William; 17069 Tulsa A61M 5/315 (2006.01) A61M 5/20 (2006.01) Street, Los Angeles, CA 91344 (US). BUSBY, Donald; 365 Hilltop Way, Thousand Oaks, CA 91362 (US). (21) International Application Number: FOLK, Christopher, R.; 12799 Briarcrest Place, San PCT/US2017/0121 10 Diego, CA 92130 (US). GIBSON, Scott, R.; 12414 Bel- (22) International Filing Date: lando Court, Granada Hills, CA 91344 (US). KOGLER, 4 January 2017 (04.01 .2017) Keith, P.; 213 Fawn Valley Court, Simi Valley, CA 93065 (US). LEE, Mark, Ka Lai; 4311 Via Cerritos, Newbury (25) Filing Language: English Park, CA 91320 (US). MCCULLOUGH, Adam, B.; 2792 (26) Publication Language: English Great Smokey Court, Westlake Village, CA 91362 (US). SHULTZ, Peter, V.; 4559 Ensenada Drive, Woodland (30) Priority Data: Hills, CA 91364 (US). TAMTORO, Ferry; 1713 E 62/275,491 6 January 2016 (06.01 .2016) US Shoreview Dr., San Ramon, CA 94582 (US). WARD, Jim- (71) Applicant: AMGEN INC. [US/US]; One Amgen Center mie, L.; 25984 Gateway Drive, Golden, CO 80459 (US). Drive, Thousand Oaks, CA 91320-1799 (US). YANG, Huaying; 878 Writer C , Vernon Hills, IL 6006 1 [Continued on nextpage] (54) Title: AUTO-INJECTOR WITH SIGNALING ELECTRONICS (57) Abstract: A drug delivery device includes a housing defining a shell com prising a front portion and a rear portion slidably coupled to the front portion, a drug delivery assembly at least partially disposed within the housing, at least one electronic component, a power source which powers the electronic component, and a switch assembly.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (CHMP) Agenda for the Meeting on 17-20 May 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
    17 May 2021 EMA/CHMP/276743/2021 Human Medicines Division Committee for medicinal products for human use (CHMP) Agenda for the meeting on 17-20 May 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes 17 May 2021, 09:00 – 19:30, virtual meeting/ room 1C 18 May 2021, 08:30 – 19:30, virtual meeting/ room 1C 19 May 2021, 08:30 – 19:30, virtual meeting/ room 1C 20 May 2021, 08:30 – 19:30, virtual meeting/ room 1C Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021.
    [Show full text]
  • Pharmacology for Students of Bachelor's Programmes at MF MU
    Pharmacology for students of bachelor’s programmes at MF MU (special part) Alena MÁCHALOVÁ, Zuzana BABINSKÁ, Jan JUŘICA, Gabriela DOVRTĚLOVÁ, Hana KOSTKOVÁ, Leoš LANDA, Jana MERHAUTOVÁ, Kristýna NOSKOVÁ, Tibor ŠTARK, Katarína TABIOVÁ, Jana PISTOVČÁKOVÁ, Ondřej ZENDULKA Text přeložili: MVDr. Mgr. Leoš Landa, Ph.D., MUDr. Máchal, Ph.D., Mgr. Jana Merhautová, Ph.D., MUDr. Jana Pistovčáková, Ph.D., Doc. PharmDr. Jana Rudá, Ph.D., Mgr. Barbora Říhová, Ph.D., PharmDr. Lenka Součková, Ph.D., PharmDr. Ondřej Zendulka, Ph.D., Mgr. Markéta Strakošová, Mgr. Tibor Štark, Jazyková korektura: Julie Fry, MSc. Obsah 2 Pharmacology of the autonomic nervous system ........................................................................ 10 2.1 Pharmacology of the sympathetic nervous system ................................................................... 10 2.1.1 Sympathomimetics ............................................................................................................... 12 2.1.2 Sympatholytics ..................................................................................................................... 17 2.2 Pharmacology of the parasympathetic system ......................................................................... 19 2.2.1 Cholinomimetics .................................................................................................................. 20 2.2.2 Parasympathomimetics ......................................................................................................... 21 2.2.3 Parasympatholytics ..............................................................................................................
    [Show full text]